Medscape: Mild Liver Enzyme Increases Seen in COVID-19 Patients in China

UC digestive diseases expert discusses COVID-19's impact on the liver

Close to 30% of COVID-19 patients presented with mildly elevated liver enzymes in a retrospective study in China. Enzyme levels did not rise significantly during hospitalization and no patients experienced liver failure, however. Kenneth Sherman, MD, PhD, Director of the UC Division of Digestive Diseases and UC Health physician, spoke with journalist Marilynn Larkin about possible liver damage associated with SARS-CoV-2 and how pre-existing liver disease could make individuals more susceptible to infection leading to COVID-19.

Read the entire interview online.

Learn more about Sherman's COVID-19 research.

Featured image at top: Kenneth Sherman, MD, PhD, shown in the UC College of Medicine. Photo/Colleen Kelley/UC Creative + Brand.

Next Lives Here

The University of Cincinnati is classified as a Research 1 institution by the Carnegie Commission and is ranked in the National Science Foundation's Top-35 public research universities. UC's graduate students and faculty investigate problems and innovate solutions with real-world impact. Next Lives Here.

Related Stories

2

UC researchers develop new CPAP device

April 17, 2024

Researchers at the University of Cincinnati are developing a VortexPAP machine that takes advantage of vortex airflow technology. A preliminary clinical study with current CPAP users demonstrated that the VortexPAP can deliver the pressure levels that are used in the subjects’ CPAP therapy, but the mask is more comfortable to wear. It has a minimalistic design that is less intrusive and barely touches the patient’s face.

Debug Query for this